Breaking News

Intuitive Surgical price target raised to $600 from $515 at Stifel. Stifel analyst Rick Wise said Intuitive Surgical "emphatically checked every important box" with its Q2 report, noting that its procedures growth, systems shipments, and EPS all meaningfully topped expectations. Following the report, he raised his 2018-2020 sales and EPS projections and increased his price target on the stock to $600. Wise keeps a Buy rating on Intuitive shares.

Intuitive Surgical price target increased to $575 from $535 at Morgan Stanley. Morgan Stanley analyst David Lewis increased his price target on Intuitive Surgical to $575 from $535, stating that "inflection in the core is evident" given the better than expected procedure growth and system upside reported in Q2. With trends in procedures and systems strong, he is confident in growth sustainability and he is additionally confident that Intuitive will not only to maintain technological leadership but materially expand its addressable market with new introductions, Lewis tells investors. He maintains an Overweight rating on Intuitive shares.

Intuitive Surgical price target raised to $620 from $510 at Cantor Fitzgerald. Cantor Fitzgerald analyst Craig Bijou raised his price target for Intuitive Surgical to $620 from $510 following last night's Q2 results. The stock in premarket trading is up 3%, or $17.71, to $539.00. Quarter after quarter, Intuitive continues to justify its premium valuation, again significantly beating on all metrics, including sales and earnings, Bijou tells investors in a post-earnings research note. He notes the company posted 18% procedure growth for Q2, one of the strongest quarterly procedure growth figures year-over-year in the last five years. The analyst believes surgical robotics "remains at an early stage" and that Intuitive Surgical will drive adoption with its existing platforms and pipeline products. Bijou reiterates an Overweight rating on the shares.

Intuitive Surgical price target raised to $550 from $460 at RBC Capital. RBC Capital analyst Brandon Henry raised his price target on Intuitive Surgical to $550 after its Q2 results, saying its momentum in general surgery continues, which allows the company to spend more to accelerate the development of its pipeline technologies. The analyst further notes that the raised procedure guidance of 14.5%-16.5% growth from 12%-15% appears reasonable, and there's potential for upside from the strong execution. Henry keeps his Sector Perform rating on Intuitive Surgical but also believes that the company is in the "early steep" part of the robotic U.S. general surgery adoption curve.

Intuitive Surgical priced appropriately for growth potential, says Canaccord. Canaccord analyst Jason Mills said Intuitive Surgical's Q2 results solidified it as the preeminent growth company in the large-cap med-tech space. The results showed the second consecutive quarter of acceleration in growth, but he feels the shares are price appropriately for its future growth potential. Mills raised his price target to $550 from $430 and maintained his Hold rating on Intuitive Surgical shares.

Intuitive Surgical price target raised to $575 from $500 at JPMorgan. JPMorgan analyst Tycho Peterson raised his price target for Intuitive Surgical to $575 saying the company last night reported "exceptionally strong" Q2 results. The company's momentum is "showing absolutely no signs of slowing," Peterson tells investors in a research note. He continues to like the set-up for Intuitive Surgical shares and reiterates an Overweight rating on the name.

Intuitive Surgical guidance range still looks conservative, Piper Jaffray says. Piper Jaffray analyst Matt O'Brien keeps his Neutral rating and $540 price target after its Q2 earnings beat, saying the results were driven by stronger than expected system sales amid robust da Vinci demand. The analyst notes that while utilization numbers moved higher, the increased procedural guidance range still looks conservative. The analyst states however that the valuation remains healthy on the stock, keeping a neutral stance in spite of the strength in the underlying business and new product cycle.